MINIZIDE
Clinical safety rating
cautionComprehensive clinical and safety monograph for MINIZIDE (MINIZIDE).
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
| Metabolism | Prazosin is extensively metabolized in the liver via O-demethylation and conjugation, primarily by CYP3A4. Polythiazide is not extensively metabolized; it is excreted unchanged in the urine. |
| Excretion | Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10% |
| Half-life | 2-3 hours (prazosin component); prolonged in heart failure or renal impairment |
| Protein binding | 97% (prazosin bound to alpha-1 acid glycoprotein and albumin) |
| Volume of Distribution | 0.6 L/kg (prazosin); reflects extensive tissue distribution |
| Bioavailability | Oral: 50-70% (prazosin); first-pass metabolism reduces systemic availability |
| Onset of Action | Oral: 1-2 hours (first-dose syncope possible within 30-90 minutes) |
| Duration of Action | 10-24 hours (antihypertensive effect); tolerability to first-dose orthostasis may persist beyond 24 hours |
| Molecular Weight | Prazosin: 383.4 Da; Polythiazide: 439.9 Da |
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
| Dosage form | CAPSULE |
| Renal impairment | Contraindicated in patients with GFR <30 mL/min. For GFR 30-60 mL/min: use with caution, reduce dose by 50%, monitor electrolytes. No adjustment for GFR >60 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment necessary. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use due to risk of hepatic encephalopathy. |
| Pediatric use | Not recommended for pediatric use due to lack of safety and efficacy data. |
| Geriatric use | Initiate therapy at the lower end of the dosing range (1 capsule daily) due to increased sensitivity to orthostatic hypotension and electrolyte disturbances. Titrate slowly. |
| 1st trimester | Contraindicated; risk of fetal malformations due to ACE inhibitor class effects. |
| 2nd trimester | Contraindicated; fetal toxicity including oligohydramnios, renal dysfunction, and skull hypoplasia. |
| 3rd trimester | Contraindicated; fetal toxicity including oligohydramnios, renal dysfunction, and skull hypoplasia. |
Clinical note
Comprehensive clinical and safety monograph for MINIZIDE (MINIZIDE).
| Placental transfer | Both components cross the placenta; prazosin shown to cross in animal studies, thiazides cross and can cause fetal effects. |
| Breastfeeding | Minizide (prazosin/polythiazide) components: prazosin is excreted in breast milk in small amounts, likely safe; polythiazide may suppress lactation. Use with caution and monitor infant for hypotension. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrolyte imbalance, and decreased placental perfusion. Avoid use unless clearly needed. |
| Fetal Monitoring | Maternal: blood pressure, serum electrolytes, renal function. Fetal: growth ultrasound, amniotic fluid index (due to diuretic effects), and fetal heart rate monitoring if used near term. |
| Fertility Effects | No well-controlled studies. Prazosin may rarely cause priapism; polythiazide may affect spermatogenesis in animal studies. Clinical significance unknown. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to prazosin, polythiazide, or sulfonamidesAnuriaConcomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil)Pregnancy
| Precautions | First-dose syncope (orthostatic hypotension) can occur, especially with initial use or dose escalation, Sodium and water depletion may occur with thiazide, leading to hypokalemia, hyponatremia, and hypomagnesemia, May exacerbate renal impairment; monitor renal function, May increase serum uric acid and precipitate gout, May cause hypersensitivity reactions, including anaphylaxis and angioedema |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges) if potassium-sparing diuretics or supplements are used; hydrochlorothiazide can cause hypokalemia so potassium-rich foods may be recommended. Grapefruit juice may increase prazosin levels; avoid. |
| Clinical Pearls | MINIZIDE (prazosin/hydrochlorothiazide) is a fixed-dose combination for hypertension. Prazosin causes first-dose syncope; start with 1 mg at bedtime. Hydrochlorothiazide may cause hypokalemia; monitor potassium. Use cautiously in patients with history of angioedema from ACE inhibitors as prazosin may also cause angioedema. |
| Patient Advice | Take first dose at bedtime to avoid fainting. · Rise slowly from sitting or lying to prevent dizziness. · Avoid alcohol as it may worsen side effects. · Report episodes of fainting or rapid heartbeat. · Do not stop abruptly; may cause rebound hypertension. |
Loading safety data…